WO2023209662 - PHARMACEUTICAL COMPOSITIONS OF SEMAGLUTIDE AND THE METHODS OF USE THEREOF
National phase entry:
Publication Number
WO/2023/209662
Publication Date
02.11.2023
International Application No.
PCT/IB2023/054435
International Filing Date
28.04.2023
Title **
[English]
PHARMACEUTICAL COMPOSITIONS OF SEMAGLUTIDE AND THE METHODS OF USE THEREOF
[French]
COMPOSITIONS PHARMACEUTIQUES DE SÉMAGLUTIDE ET LEURS MÉTHODES D'UTILISATION
Applicants **
PENTIDE THERAPEUTICS LIMITED
Inventors
WANG, Yanfeng
XU, Liang
LAM, Wai Han
Priority Data
63/337,031
29.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2132 | |
| EPO | Filing, Examination, Granting | 18962 | |
| Japan | Filing, Examination, Granting | 2639 | |
| South Korea | Filing, Examination, Granting | 2982 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
33,255
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Pharmaceutical compositions of semaglutide or its salts for intranasal administration in the treatment of diabetes mellitus, obesity, nonalcoholic fatty liver disease (NAFLD), or neurodegenerative diseases. A method comprising the delivery of semaglutide via intranasal route avoids repeated injections and improves systemic absorption as compared to an oral tablet.[French]
L'invention concerne des compositions pharmaceutiques de sémaglutide ou de ses sels pour une administration intranasale dans le traitement du diabète sucré, de l'obésité, d'une stéatose hépatique non alcoolique (NAFLD) ou de maladies neurodégénératives. Une méthode comprenant l'administration de sémaglutide par voie intranasale évite des injections répétées et améliore l'absorption systémique en comparaison avec une tablette orale.